MASIMO CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 135.2 USD | -0.50% |
|
-0.50% | +15.38% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 68.11 and 46.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +14.11% | 7.19B | C- | ||
| +72.48% | 12.34B | B- | ||
| -19.07% | 7.98B | C+ | ||
| +2.18% | 5.81B | B | ||
| +6.51% | 5.04B | D+ | ||
| +21.99% | 4.31B | - | ||
| -20.27% | 4.03B | B- | ||
| -41.14% | 2.21B | C | ||
| +0.87% | 1.99B | - | ||
| +2.93% | 1.87B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MASI Stock
- Ratings Masimo Corporation
